Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer.

Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.


Clinical Trial Description

A total of 20 patients may be enrolled over a period of 1-2 years. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02873390
Study type Interventional
Source Ningbo Cancer Hospital
Contact Bi Wang
Phone 86-13310088259
Email biwang0218@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date August 2016
Completion date July 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Completed NCT00948961 - A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Terminated NCT02265510 - An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Phase 1/Phase 2
Completed NCT03907969 - A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. Phase 1/Phase 2
Completed NCT03241173 - A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Phase 1/Phase 2
Completed NCT02923349 - A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04025957 - A Study of SHR-1501 in Patients With Advanced Tumors Phase 1
Recruiting NCT05048134 - A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies Phase 1
Completed NCT00651664 - A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies Phase 1
Not yet recruiting NCT06038058 - A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies Phase 1
Completed NCT00611793 - PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies Phase 1
Recruiting NCT05891171 - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Phase 1
Not yet recruiting NCT05987605 - Clinical Study of 1A46 Drug Substance Phase 1
Terminated NCT02608268 - Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Phase 1/Phase 2
Terminated NCT03277352 - INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Phase 1/Phase 2
Recruiting NCT05577182 - Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies Phase 1
Completed NCT04831996 - To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. Phase 1
Recruiting NCT06468098 - A Study of IBI363 in Subjects With Advanced Malignancies Phase 1
Completed NCT02737501 - ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Phase 3